129 related articles for article (PubMed ID: 22263785)
1. CDK1 hyperphosphorylation maintenance drives the time-course of G2-M cell cycle arrest after short treatment with NAMI-A in Kb cells.
Bergamo A; Delfino R; Casarsa C; Sava G
Anticancer Agents Med Chem; 2012 Oct; 12(8):949-58. PubMed ID: 22263785
[TBL] [Abstract][Full Text] [Related]
2. Tumour cell uptake G2-M accumulation and cytotoxicity of NAMI-A on TS/A adenocarcinoma cells.
Bergamo A; Zorzet S; Cocchietto M; Carotenuto ME; Magnarin M; Sava G
Anticancer Res; 2001; 21(3B):1893-8. PubMed ID: 11497274
[TBL] [Abstract][Full Text] [Related]
3. Ruthenium-based NAMI-A type complexes with in vivo selective metastasis reduction and in vitro invasion inhibition unrelated to cell cytotoxicity.
Bergamo A; Gava B; Alessio E; Mestroni G; Serli B; Cocchietto M; Zorzet S; Sava G
Int J Oncol; 2002 Dec; 21(6):1331-8. PubMed ID: 12429985
[TBL] [Abstract][Full Text] [Related]
4. In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin.
Bergamo A; Gagliardi R; Scarcia V; Furlani A; Alessio E; Mestroni G; Sava G
J Pharmacol Exp Ther; 1999 Apr; 289(1):559-64. PubMed ID: 10087050
[TBL] [Abstract][Full Text] [Related]
5. The hydrolysis of the anti-cancer ruthenium complex NAMI-A affects its DNA binding and antimetastatic activity: an NMR evaluation.
Bacac M; Hotze AC; van der Schilden K; Haasnoot JG; Pacor S; Alessio E; Sava G; Reedijk J
J Inorg Biochem; 2004 Feb; 98(2):402-12. PubMed ID: 14729322
[TBL] [Abstract][Full Text] [Related]
6. Effects of NAMI-A and some related ruthenium complexes on cell viability after short exposure of tumor cells.
Bergamo A; Zorzet S; Gava B; Sorc A; Alessio E; Iengo E; Sava G
Anticancer Drugs; 2000 Sep; 11(8):665-72. PubMed ID: 11081461
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of adhesion, migration and of α5β1 integrin in the HCT-116 colorectal cancer cells treated with the ruthenium drug NAMI-A.
Pelillo C; Mollica H; Eble JA; Grosche J; Herzog L; Codan B; Sava G; Bergamo A
J Inorg Biochem; 2016 Jul; 160():225-35. PubMed ID: 26961176
[TBL] [Abstract][Full Text] [Related]
8. Effects of the ruthenium-based drug NAMI-A on the roles played by TGF-β1 in the metastatic process.
Brescacin L; Masi A; Sava G; Bergamo A
J Biol Inorg Chem; 2015 Oct; 20(7):1163-73. PubMed ID: 26369538
[TBL] [Abstract][Full Text] [Related]
9. Actin-dependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-A.
Sava G; Frausin F; Cocchietto M; Vita F; Podda E; Spessotto P; Furlani A; Scarcia V; Zabucchi G
Eur J Cancer; 2004 Jun; 40(9):1383-96. PubMed ID: 15177498
[TBL] [Abstract][Full Text] [Related]
10. A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.
Rademaker-Lakhai JM; van den Bongard D; Pluim D; Beijnen JH; Schellens JH
Clin Cancer Res; 2004 Jun; 10(11):3717-27. PubMed ID: 15173078
[TBL] [Abstract][Full Text] [Related]
11. Tumour cell uptake of the metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells.
Frausin F; Cocchietto M; Bergamo A; Scarcia V; Furlani A; Sava G
Cancer Chemother Pharmacol; 2002 Nov; 50(5):405-11. PubMed ID: 12439599
[TBL] [Abstract][Full Text] [Related]
12. Ruthenium antimetastatic agents.
Alessio E; Mestroni G; Bergamo A; Sava G
Curr Top Med Chem; 2004; 4(15):1525-35. PubMed ID: 15579094
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological control of lung metastases of solid tumours by a novel ruthenium complex.
Sava G; Capozzi I; Clerici K; Gagliardi G; Alessio E; Mestroni G
Clin Exp Metastasis; 1998 May; 16(4):371-9. PubMed ID: 9626816
[TBL] [Abstract][Full Text] [Related]
14. Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen.
Sava G; Zorzet S; Turrin C; Vita F; Soranzo M; Zabucchi G; Cocchietto M; Bergamo A; DiGiovine S; Pezzoni G; Sartor L; Garbisa S
Clin Cancer Res; 2003 May; 9(5):1898-905. PubMed ID: 12738748
[TBL] [Abstract][Full Text] [Related]
15. Reduction of lung metastasis by ImH[trans-RuCl4(DMSO)Im]: mechanism of the selective action investigated on mouse tumors.
Sava G; Clerici K; Capozzi I; Cocchietto M; Gagliardi R; Alessio E; Mestroni G; Perbellini A
Anticancer Drugs; 1999 Jan; 10(1):129-38. PubMed ID: 10194556
[TBL] [Abstract][Full Text] [Related]
16. Jaridonin-induced G2/M phase arrest in human esophageal cancer cells is caused by reactive oxygen species-dependent Cdc2-tyr15 phosphorylation via ATM-Chk1/2-Cdc25C pathway.
Ma YC; Su N; Shi XJ; Zhao W; Ke Y; Zi X; Zhao NM; Qin YH; Zhao HW; Liu HM
Toxicol Appl Pharmacol; 2015 Jan; 282(2):227-36. PubMed ID: 25450480
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines.
Pluim D; van Waardenburg RC; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2004 Jul; 54(1):71-8. PubMed ID: 15034754
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine).
Velders AH; Bergamo A; Alessio E; Zangrando E; Haasnoot JG; Casarsa C; Cocchietto M; Zorzet S; Sava G
J Med Chem; 2004 Feb; 47(5):1110-21. PubMed ID: 14971891
[TBL] [Abstract][Full Text] [Related]
19. Lack of In vitro cytotoxicity, associated to increased G(2)-M cell fraction and inhibition of matrigel invasion, may predict In vivo-selective antimetastasis activity of ruthenium complexes.
Zorzet S; Bergamo A; Cocchietto M; Sorc A; Gava B; Alessio E; Iengo E; Sava G
J Pharmacol Exp Ther; 2000 Dec; 295(3):927-33. PubMed ID: 11082425
[TBL] [Abstract][Full Text] [Related]
20. Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activity.
Novohradský V; Bergamo A; Cocchietto M; Zajac J; Brabec V; Mestroni G; Sava G
Dalton Trans; 2015 Jan; 44(4):1905-13. PubMed ID: 25489765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
